D
Enliven Therapeutics, Inc. ELVN
$16.86 -$1.91-10.18% NASDAQ
Recommendation
Prev Close
$16.86
Volume
1,407,974
Avg Vol (90D)
555,998
Market Cap
$1.00B
Dividend & Yield
--
52-Week Range
$13.30 - $25.37
P/E (TTM)
--
EPS (TTM)
-$1.85
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
5AM Venture Management LLC Reduces Stock Holdings in Enliven Therapeutics, Inc. $ELVN
12/13/2025 - MarketBeat
Enliven Therapeutics (ELVN, $18.77) price may climb as it broke lower Bollinger Band on Dec 11, 2025
12/12/2025 - Tickeron - Stocks
Enliven Therapeutics (NASDAQ:ELVN) COO Anish Patel Sells 6,663 Shares of Stock
12/12/2025 - MarketBeat
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
12/11/2025 - GuruFocus
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
12/11/2025 - PR Newswire
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 6.5% Following Insider Selling
12/11/2025 - MarketBeat
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development
12/11/2025 - GuruFocus
Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) COO Sells 6,663 Shares of Stock
12/11/2025 - MarketBeat
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development
12/11/2025 - PR Newswire
Enliven Therapeutics (ELVN, $19.49) price may climb as it broke lower Bollinger Band on Dec 09, 2025
12/10/2025 - Tickeron - Technical Analysis
Enliven Therapeutics (NASDAQ:ELVN) Sees Unusually-High Trading Volume - Here's What Happened
12/9/2025 - MarketBeat
ELVN Makes Notable Cross Below Critical Moving Average
12/9/2025 - Nasdaq News: Stocks
ELVN Makes Notable Cross Below Critical Moving Average
12/9/2025 - Market News Video
Enliven Therapeutics (ELVN, $20.52) price exceeded its 50-day Moving Average on December 08, 2025
12/9/2025 - Tickeron - Technical Analysis
Enliven Therapeutics (ELVN, $20.52) entered Downtrend as Momentum indicator drops below 0 level on Dec 08, 2025
12/9/2025 - Tickeron - Technical Analysis
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of "Moderate Buy" from Brokerages
12/8/2025 - MarketBeat
Enliven Therapeutics (ELVN, $21.81) entered Uptrend as Momentum indicator ascends above 0 level on Dec 05, 2025
12/6/2025 - Tickeron - Stocks
Enliven Therapeutics (ELVN, $21.4) Stochastic Oscillator left the oversold zone on December 04, 2025
12/5/2025 - Tickeron - Stocks
Enliven Therapeutics (ELVN): Assessing Valuation After a Recent 13% Share Price Rebound
12/5/2025 - Simply Wall St
Enliven Therapeutics (ELVN, $21) price moved above its 50-day Moving Average on December 03, 2025
12/5/2025 - Tickeron - Technical Analysis
Enliven Therapeutics (ELVN, $20.56) Stochastic Oscillator left the oversold zone on December 02, 2025
12/3/2025 - Tickeron - Stocks
Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade
12/3/2025 - Zacks Investment Research
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 8% - Time to Sell?
12/2/2025 - MarketBeat
Enliven Therapeutics (ELVN, $19.85) price exceeded its 50-day Moving Average on December 01, 2025
12/2/2025 - Tickeron - Stocks
Enliven Therapeutics (ELVN, $19.85) entered Downtrend as Momentum indicator drops below 0 level on Dec 01, 2025
12/2/2025 - Tickeron - Stocks
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$111.97M
EBIT (TTM)
-$112.27M
Net Income (TTM)
-$97.21M
Balance Sheet
Total Assets (Q)
$490.88M
Total Debt (Q)
$490.00K
Total Liabilities (Q)
$14.75M
Book Value Per Share (Q)
$8.03
Cash Flow
Cash from Operations (TTM)
-$71.67M
Cash from Investing (TTM)
-$185.49M
Cash from Financing (TTM)
$258.22M
Net Change in Cash (TTM)
$1.06M
Filings
Filing Date
Wednesday, November 12, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 9 and 13 (est)
Price History
Loading...
Beta
2.10
7-Day Total Return
-21.22%
30-Day Total Return
-28.01%
60-Day Total Return
-11.08%
90-Day Total Return
-5.81%
Year to Date Total Return
-29.46%
1-Year Total Return
-27.17%
2-Year Total Return
48.94%
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Apr 10, 2025 - $13.30
52-week High
Jan 03, 2025 - $25.37
Valuation
Market Cap
$1.00B - Small Cap
Enterprise Value
$523.52M
Price/Sales (TTM)
--
Price/Book (Q)
2.10
Dividends and Shares
Shares Outstanding
62.09
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.enliventherapeutics.com
Phone Number
720 647 8519
Address
6200 Lookout Road
Boulder, CO 80301
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead... more
NASDAQ 12/12/2025 4:00PM Eastern Quotes delayed